News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
BioSpace News Archive
Browse BioSpace’s published news and press releases by year, month, and day.
137 Results
Year
2005 (24679)
2006 (34770)
2007 (39687)
2008 (39410)
2009 (42118)
2010 (39616)
2011 (38383)
2012 (38416)
2013 (36268)
2014 (39673)
2015 (44433)
2016 (38330)
2017 (37191)
2018 (39124)
2019 (51338)
2020 (57666)
2021 (58724)
2022 (53928)
2023 (42568)
2024 (38486)
2025 (17535)
Month
January (2946)
February (2976)
March (2714)
April (2913)
May (3639)
June (2347)
Day
2 (202)
3 (126)
4 (116)
5 (124)
6 (51)
9 (127)
10 (95)
11 (131)
12 (128)
13 (61)
16 (159)
17 (116)
18 (142)
19 (71)
20 (36)
23 (191)
24 (140)
25 (137)
26 (113)
27 (81)
Year
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Month
January
February
March
April
May
June
Day
2
3
4
5
6
9
10
11
12
13
16
17
18
19
20
23
24
25
26
27
Vaccines
What To Watch for as ACIP’s New Era Begins
The newly appointed members of the CDC’s influential vaccine committee meet Wednesday and Thursday under an unusually rapid timeline, with unexpected topics on the agenda.
June 25, 2025
·
3 min read
·
Dan Samorodnitsky
Business
TIGIT Turmoil: How Pharma Burned Billions on Failed Immuno-Oncology Projects
Leading companies spent $1.4 billion upfront on licensing deals and embarked on vast R&D programs. Clinical setbacks mean many companies are unlikely to ever recoup their investments.
June 25, 2025
·
5 min read
·
Nick Paul Taylor
Press Releases
Priothera Secures €1.7 million i-Nov Funding by Bpifrance for Rare Blood Cancer Clinical Program
June 25, 2025
·
4 min read
Press Releases
CytoSorbents Files Appeal with U.S. FDA for Supervisory Review of its De Novo Request for DrugSorb™-ATR
June 25, 2025
·
8 min read
Press Releases
Candel Therapeutics Announces $15 million Registered Direct Offering of Common Stock
June 25, 2025
·
7 min read
Press Releases
Revolution Medicines Enters Into $2 Billion Flexible Funding Agreement with Royalty Pharma to Support Global Development and Commercialization of RAS(ON) Inhibitor Portfolio for Patients with RAS-Addicted Cancers
June 25, 2025
·
9 min read
Press Releases
RECORDATI ANNOUNCES EXCLUSIVE LICENSING & SUPPLY AGREEMENT WITH AMARIN TO COMMERCIALIZE VAZKEPA® IN EUROPE
June 25, 2025
·
4 min read
Press Releases
Pioneering New Study Finds Most U.S. Babies Lack Key Gut Bacteria, Increasing Risk for Allergies and Other Chronic Health Issues
June 25, 2025
·
3 min read
Press Releases
MicroPure Genomics Awarded Competitive $1.25M SBIR Phase II Grant from the National Science Foundation
June 25, 2025
·
2 min read
Press Releases
Fortrea & Emery Pharma Announce Strategic Collaboration to Deliver FDA Compliant Drug-Drug-Interaction Studies Using Rifampin
June 25, 2025
·
5 min read
Previous
2 of 14
Next